Phosphoproteomic analysis reveals PAK2 as a therapeutic target for lapatinib resistance in HER2-positive breast cancer cells

다국어 초록 (Multilingual Abstract)

<P><B>Abstract</B></P> <P>The human epidermal growth factor receptor 2 (HER2)-positive breast cancer with overexpression of HER2 accounts for approximately 25% of breast cancers and is more aggressive than other types of breast cancer. Lapatinib has been widely used as a HER2-targeted therapy, however, a number of patients develop lapatinib resistance and still suffer from poor prognosis. Therefore, it is essential to identify novel therapeutic targets that could overcome lapatinib resistance. In this study, we carried out phosphoproteomic analysis of lapatinib sensitive and resistant cell lines (SKBR3 and SKBR3-LR) using stable isotope labeling with amino acids in cell culture (SILAC). We identified 3808 phosphopeptides from 1807 proteins and then analyzed signaling pathways, Gene Ontology, and protein-protein interaction networks. Finally, we identified PAK2 as a therapeutic target from the network analysis and validated that PAK2 knockdown and PAK inhibitor treatment resensitize the lapatinib resistant cells to lapatinib. This results suggest that PAK2 is a potent therapeutic target to overcome acquired lapatinib resistance in HER2-positive breast cancer cells.</P> <P><B>Highlights</B></P> <P> <UL> <LI> Phosphoproteomic analysis identified PAK2 as a drug target for lapatinib resistance. </LI> <LI> PAK2 knockdown restores lapatinib sensitivity of lapatinib-resistant SKBR-LR cells. </LI> <LI> Cotreatment of lapatinib with PAK inhibitor restores the sensitivity to lapatinib. </LI> </UL> </P>